Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 4Rituximab 3Immunoglobulin G 3Everolimus 3Disulfides 3Cyclosporine 3pembrolizumab 2mogamulizumab 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2ProMune 2Photopheresis 2Mycophenolic Acid 2Methotrexate 2Lenalidomide 2Gene Expression Profiling 2Etoposide 2Cyclophosphamide 2Busulfan 2Bortezomib 2veliparib 1romidepsin 1navitoclax 1magrolimab 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mycosis Fungoides × navitoclax × Clear all
NCT00406809 2021-08-02

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

AbbVie

Phase 1/2 Completed
81 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡